Epha2 is a critical oncogene in melanoma

被引:0
|
作者
D Udayakumar
G Zhang
Z Ji
C-N Njauw
P Mroz
H Tsao
机构
[1] Massachusetts General Hospital,Department of Dermatology
[2] Wellman Center for Photomedicine,Department of Dermatology
[3] Harvard Medical School,Department of Surgery
[4] Massachusetts General Hospital,undefined
[5] Center for Vascular Biology Research,undefined
[6] Beth Israel Deaconess Medical Center,undefined
[7] Harvard Medical School,undefined
[8] Melanoma and Pigmented Lesion Center,undefined
[9] Massachusetts General Hospital,undefined
来源
Oncogene | 2011年 / 30卷
关键词
melanoma; EphA2; survival;
D O I
暂无
中图分类号
学科分类号
摘要
EphA2 is a member of the Eph family of receptor tyrosine kinases and is highly expressed in many aggressive cancer types, including melanoma. We recently showed that EphA2 is also upregulated by ultraviolet radiation and is able to induce apoptosis. These findings suggest that EphA2 may have different, even paradoxical, effects on viability depending on the cellular context and that EphA2 mediates a delicate balance between life and death of the cell. To functionally clarify EphA2's role in melanoma, we analyzed a panel of melanoma cell lines and found that EphA2 levels are elevated in a significant fraction of the samples. Specific depletion of EphA2 in high-expressing melanoma cells using short hairpin RNA led to profound reductions in cellular viability, colony formation and migration in vitro and a dramatic loss of tumorigenic potential in vivo. Stable introduction of EphA2 into low-expressing cell lines enhanced proliferation, colony formation and migration, further supporting its pro-malignant phenotype. Interestingly, transient expression of EphA2 and/or BrafV600E in non-transformed melanocytes led to significant and additive apoptosis. These results verify that EphA2 is an important oncogene and potentially a common source of ‘addiction’ for many melanoma cells. Moreover, acute induction of EphA2 may purge genetically susceptible cells, thereby uncovering a more aggressive population that is in fact dependent on the oncogene.
引用
收藏
页码:4921 / 4929
页数:8
相关论文
共 50 条
  • [1] Epha2 is a critical oncogene in melanoma
    Udayakumar, D.
    Zhang, G.
    Ji, Z.
    Njauw, C-N
    Mroz, P.
    Tsao, H.
    ONCOGENE, 2011, 30 (50) : 4921 - 4929
  • [2] EphA2 as a promoter of melanoma tumorigenicity
    Margaryan, Naira V.
    Strizzi, Luigi
    Abbott, Daniel E.
    Seftor, Elisabeth A.
    Rao, M. Sambasiva
    Hendrix, Mary J. C.
    Hess, Angela R.
    CANCER BIOLOGY & THERAPY, 2009, 8 (03) : 275 - 284
  • [3] Effects of EphA2 receptor regulation on metastasis of melanoma cells
    Mosch, B.
    Neuber, C.
    Reissenweber, B.
    Tandler, N.
    Pietzsch, J.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 : 89 - 89
  • [4] EphA2 as a target for adenoviral gene transfer or oncolysis of malignant melanoma
    Behr, M.
    Richter, M.
    Haeusl, M. A.
    Engelhardt, S.
    Eskerski, H.
    Ehrhardt, A.
    Enk, A. H.
    Nettelbeck, D. M.
    EXPERIMENTAL DERMATOLOGY, 2012, 21 (03) : e42 - e43
  • [5] EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
    Miao, Benchun
    Ji, Zhenyu
    Tan, Li
    Taylor, Michael
    Zhang, Jianming
    Choi, Hwan Geun
    Frederick, Dennie T.
    Kumar, Raj
    Wargo, Jennifer A.
    Flaherty, Keith T.
    Gray, Nathanael S.
    Tsao, Hensin
    CANCER DISCOVERY, 2015, 5 (03) : 274 - 287
  • [6] EphA2 and ephrinA1: An oncogene/tumor suppressor system in glioblastoma multiforme?
    Wykosky, Jill
    Debinski, Waldemar
    CANCER RESEARCH, 2006, 66 (08)
  • [7] The landscape of EPHA2 inhibition
    Kudlinzki, Denis
    Heinzlmeir, Stephanie
    Kuster, Bernhard
    Schwalbe, Harald
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2017, 73 : A223 - A224
  • [8] Targeting EphA2 in cancer
    Xiao, Ta
    Xiao, Yuhang
    Wang, Wenxiang
    Tang, Yan Yan
    Xiao, Zhiqiang
    Su, Min
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
  • [9] EphA2与肿瘤
    蒋莎莉
    罗招阳
    国际病理科学与临床杂志, 2008, (05) : 412 - 415
  • [10] Targeting EphA2 in cancer
    Ta Xiao
    Yuhang Xiao
    Wenxiang Wang
    Yan Yan Tang
    Zhiqiang Xiao
    Min Su
    Journal of Hematology & Oncology, 13